Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)